ArticleBlood2015
How I treat Langerhans cell histiocytosis.
Article in Blood, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06582745 (Targeted Approach to Langerhans Cell Histiocytosis), which is not on this map. Cited by 83 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Who cites it
83 citing papers in PubMed, 1 synthesis or guideline pooled it, 234 citations in OpenAlex.
- Isolated clival Langerhans cell histiocytosis in a pediatric patient: systematic review and illustrative case report.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Trial
- Trial
- Watchful waiting in children with unifocal osseous Langerhans cell histiocytosis.The oncologist · 2026Article
- An Unusual Presentation of Multisystem Langerhans Cell Histiocytosis in a Child: A Case Report.Cureus · 2026Article
- Article
- Dabrafenib or trametinib in pediatric Langerhans cell histiocytosis with bone lesions: a retrospective efficacy and safety study.BMC cancer · 2026Article
- Age-Stratified Imaging Selection in Langerhans Cell Histiocytosis: Towards a Clinical Decision Framework.Journal of clinical medicine · 2026Article
- Survival outcomes and adverse prognostic factors of Langerhans cell histiocytosis: a 40-year experience from a single tertiary center in Thailand.Annals of hematology · 2026Article
- At the crossroads of infection and malignancy: the challenge of tuberculosis in migrating populations - Case Report and Epidemiologic Analysis.BMC infectious diseases · 2025Article
- Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment.Hematology. American Society of Hematology. Education Program · 2025Review
- Growing intradiploic epidermoid cyst presenting as a diagnostic challenge in the setting of Langerhans cell histiocytosis: A case report.Radiology case reports · 2025Article
- High CCR6 expression increases the risk of pediatric Langerhans cell histiocytosis.Blood science (Baltimore, Md.) · 2025Article
- Approach to the Patient: From Endocrinopathy to the Diagnosis of a Histiocytic Disorder.The Journal of clinical endocrinology and metabolism · 2025Review
- Dermatologic Lesions with Eosinophilia in the Head and Neck.Head and neck pathology · 2025Review
- Insights into etiology and management of a case of Langerhans cell histiocytosis manifesting as perianal lesions: a case report.Journal of medical case reports · 2025Article
- Socioeconomic characteristics and relapse-free and overall survival from childhood cancer - a nationwide study based on data from the Danish Childhood Cancer Registry.Acta oncologica (Stockholm, Sweden) · 2025Article
- Langerhans Cell Histiocytosis Successfully Treated with Combination of Thalidomide and Corticosteroid.European journal of case reports in internal medicine · 2025Article
- Updates on Langerhans cell histiocytosis and other histiocytosis in children: invited review-challenges and novelties in paediatric tumours.Virchows Archiv : an international journal of pathology · 2025Review
- Case Report: A concomitant case of eosinophilic granuloma of the spine andFrontiers in surgery · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
"Langerhans cell histiocytosis" (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology of CD1a(+)/CD207(+) dendritic cells with characteristic morphology among an inflammatory infiltrate. Despite historical uncertainty defining LCH as inflammatory vs neoplastic and incomplete understanding of mechanisms of pathogenesis, clinical outcomes have improved markedly over the past decades through cooperative randomized clinical trials based on empiric therapeutic strategies. Significant advances include recognition of high- and low-risk clinical groups defined by hematopoietic and/or hepatic involvement, and of the importance of optimal intensity and of duration of chemotherapy. Nevertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage strategies, and significant disease morbidity of both high- and low-risk patients remain challenges. Recent discovery of recurrent somatic mutations in mitogen-activated protein kinase pathway genes at critical stages of myeloid hematopoietic differentiation in LCH patients supports redefinition of the disease as a myeloproliferative disorder and provides opportunities to develop novel approaches to diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.